Hmd Biomedical Inc. Sustainability Profile
HMD Biomedical Inc., a leading name in the biomedical industry, is headquartered in Taiwan (TW) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a pioneer in the development of innovative medical devices and diagnostic solutions, focusing on enhancing patient care and clinical efficiency. HMD Biomedical's core offerings include advanced point-of-care testing systems and high-quality laboratory equipment, distinguished by their precision and user-friendly design. The company has achieved significant milestones, including numerous certifications and partnerships that underscore its commitment to quality and innovation. With a strong market position, HMD Biomedical continues to drive advancements in healthcare technology, making a notable impact in the medical field.
DitchCarbon Score
How does Hmd Biomedical Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hmd Biomedical Inc.'s score of 25 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hmd Biomedical Inc.'s reported carbon emissions
In 2023, Hmd Biomedical Inc. reported total carbon emissions of approximately 350,000,000 kg CO2e from Scope 1 and 2, alongside a significant Scope 3 total of about 34,650,000,000 kg CO2e. This marks a reduction from 2022, where emissions were approximately 390,000,000 kg CO2e for Scope 1 and 2, and about 38,610,000,000 kg CO2e for Scope 3. Despite these figures, Hmd Biomedical Inc. has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not inherit emissions data from a parent organization, indicating that its reported figures are solely its own. Overall, while Hmd Biomedical Inc. has shown a decrease in emissions year-on-year, the lack of formal climate commitments or reduction strategies suggests an area for potential improvement in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 38,610,000,000 | 00,000,000,000 |
How Carbon Intensive is Hmd Biomedical Inc.'s Industry?
How Carbon Intensive is Hmd Biomedical Inc.'s Location?
Hmd Biomedical Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hmd Biomedical Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
